Search PubMedSearch

PubMed · 42754672

Species distribution models predict genome-wide polymorphism and gene flow in an endangered amphibian.

Abstract

Species distribution models (SDMs) are widely used to predict habitat suitability but their usefulness and accuracy for inferring population health is still debated. Here, we evaluate whether SDM-derived relative habitat suitability (RHS) predicts genome-wide genetic diversity and connectivity-which are key proxies for population health and the functional integrity of landscapes. We addressed this issue in the Yellow-bellied toad (Bombina variegata), an endangered amphibian species with limited dispersal. We combined hierarchical SDMs, integrating both continental-level bioclimatic data and regional-level landscape variables, with genome-wide SNP data from 404 individuals sampled across 92 sites in southeastern France. We then used a multi-scale modelling framework to test the effect of bioclimatic (BRHS) and landscape (LRHS) habitat suitability on observed heterozygosity and pairwise genetic differentiation, accounting for heterogeneous genetic drift using gravity models. Our results show that both BRHS and LRHS are significant predictors of heterozygosity, with their effects expressed at different spatial scales-11 km and 3 km for BRHS and LRHS, respectively. Connectivity patterns also widely varied depending on scale and were best explained by gravity models integrating LRHS, BRHS, and local heterozygosity, underscoring the combined role of landscape resistance and population size in shaping patterns of genetic differentiation. These findings show that SDMs, when carefully calibrated and interpreted, can provide proxies for genetic diversity and landscape resistance in species with limited dispersal.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Benjamin Monod-Broca, Hugo Cayuela, Jérôme G Prunier, Lelio Belloir, Igor Boyer, Francis Isselin-Nondedeu, Glenn Yannic, Heike Pröhl, Quentin Rougemont, Jean-Paul Léna. 2026-09-17. Species distribution models predict genome-wide polymorphism and gene flow in an endangered amphibian.. https://doi.org/10.1038/s41437-026-00885-y

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article